Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (38)	4/22/2003 8:16:46 PM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 4232

ACTC Nasdaq 1.16: (COMTEX) B: CombiMatrix Announces First SARS Virus Microarray B: CombiMatrix Announces First SARS Virus Microarray NEWPORT BEACH, Calif., Apr 15, 2003 (BUSINESS WIRE) -- Acacia Research Corporation (Nasdaq:ACTG)(Nasdaq:CBMX) announced today that CombiMatrix has designed and fabricated the first microarray based on the SARS (Severe Acute Respiratory Syndrome) coronavirus genome published earlier this week. The first microarrays were fabricated within 48 hours of publication of the coronavirus genome sequence believed to be responsible for SARS, underscoring CombiMatrix' ability to rapidly design and build custom microarrays. Researchers at the Centers for Disease Control in Atlanta and at the Michael Smith Genome Sciences Centre in Canada independently announced on Monday that they sequenced the coronavirus genome in an unprecedented 31 days. CombiMatrix technology builds on this momentum by enabling researchers with a fast turnaround custom microarray system. Researchers can now apply this technology to confirm the link between the coronavirus and SARS as well as helping to develop tests to screen for the virus and to develop potential medicines for treating the syndrome. "Our technology platform is ideally suited to taking new genetic sequence information and fabricating a corresponding microarray so researchers and clinicians have a tool for rapid studies," said Dr. Amit Kumar, President and CEO of CombiMatrix. "This SARS chip is designed using the sequence data published this week. We anticipate that researchers will want to make multiple versions of this chip as we learn more about the virus." ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The Acacia Technologies group licenses its DMT and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications, from DNA synthesis/diagnostics to immunochemical detection. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. CONTACT: Acacia Research Corporation Bret L. Undem, Media Relations, 425/493-2293 Fax 425/493-2010 URL: businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved. -0- KEYWORD: GEORGIA CALIFORNIA INTERNATIONAL CANADA INDUSTRY KEYWORD: TELECOMMUNICATIONS SOFTWARE HARDWARE MEDICAL BIOTECHNOLOGY PRODUCT SOURCE: Acacia Research Corporation * end of story *